KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Depreciation & Amortization (CF): 2011-2025

Historic Depreciation & Amortization (CF) for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Sep 2025 value amounting to $24.8 million.

  • Supernus Pharmaceuticals' Depreciation & Amortization (CF) rose 23.40% to $24.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $85.4 million, marking a year-over-year increase of 2.58%. This contributed to the annual value of $80.4 million for FY2024, which is 5.24% down from last year.
  • Supernus Pharmaceuticals' Depreciation & Amortization (CF) amounted to $24.8 million in Q3 2025, which was up 16.14% from $21.4 million recorded in Q2 2025.
  • In the past 5 years, Supernus Pharmaceuticals' Depreciation & Amortization (CF) ranged from a high of $24.8 million in Q3 2025 and a low of $6.6 million during Q1 2021.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $20.7 million (2023), whereas its average is $21.1 million.
  • Over the last 5 years, Supernus Pharmaceuticals' Depreciation & Amortization (CF) had its largest YoY gain of 280.60% in 2021, and its largest YoY loss of 14.89% in 2021.
  • MRQ analysis of 5 years shows Supernus Pharmaceuticals' Depreciation & Amortization (CF) stood at $12.7 million in 2021, then soared by 64.07% to $20.8 million in 2022, then grew by 3.97% to $21.7 million in 2023, then dropped by 13.06% to $18.8 million in 2024, then soared by 31.63% to $24.8 million in 2025.
  • Its Depreciation & Amortization (CF) was $24.8 million in Q3 2025, compared to $21.4 million in Q2 2025 and $20.4 million in Q1 2025.